We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Horizon Therapeutics Public Limited Company (“Horizon Therapeutics” or the “Company”) (NASDAQ: HZNP) in connection with the proposed acquisition of the Company by Amgen Inc. (NASDAQ: AMGN).  Under the terms of the merger agreement, the Company’s shareholders will receive $116.50 in cash for each share of Horizon Therapeutics common stock owned.

Weiss Law is investigating whether (i) Horizon Therapeutics’ board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $116.50 per share merger consideration adequately compensates Horizon Therapeutics’ shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. Notably, at least one analyst set a price target for the Company of $140 per share, $23.50 above the per-share merger consideration.